1. Home
  2. SBFG vs GANX Comparison

SBFG vs GANX Comparison

Compare SBFG & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SB Financial Group Inc.

SBFG

SB Financial Group Inc.

HOLD

Current Price

$23.65

Market Cap

134.8M

Sector

Finance

ML Signal

HOLD

Logo Gain Therapeutics Inc.

GANX

Gain Therapeutics Inc.

HOLD

Current Price

$3.98

Market Cap

159.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SBFG
GANX
Founded
1983
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
134.8M
159.2M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
SBFG
GANX
Price
$23.65
$3.98
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$8.00
AVG Volume (30 Days)
14.4K
1.2M
Earning Date
01-22-2026
11-12-2025
Dividend Yield
2.69%
N/A
EPS Growth
21.17
N/A
EPS
2.11
N/A
Revenue
$63,406,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$10.90
N/A
Revenue Growth
11.76
N/A
52 Week Low
$17.10
$1.41
52 Week High
$24.48
$4.34

Technical Indicators

Market Signals
Indicator
SBFG
GANX
Relative Strength Index (RSI) 67.08 69.52
Support Level $21.19 $3.94
Resistance Level $23.77 $4.34
Average True Range (ATR) 0.78 0.38
MACD 0.20 0.04
Stochastic Oscillator 96.30 77.78

Price Performance

Historical Comparison
SBFG
GANX

About SBFG SB Financial Group Inc.

SB Financial Group Inc that provides a range of community banking services, including commercial and consumer lending, personal and business banking, treasury management and merchant services, personal wealth management and brokerage services, and other financial services to individuals, businesses, and municipalities. It operates in single segment which is Banking.

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.

Share on Social Networks: